T
VRTX icon

Tidemark’s Vertex Pharmaceuticals VRTX Stock Holding History

Tidemark’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.4K Sell
25
-1
-4% -$443 ﹤0.01% 483
2026
Q1 		$11.6K Buy
26
+3
+13% +$1.4K ﹤0.01% 448
2025
Q4 		$10.4K Sell
23
-5
-18% -$2.15K ﹤0.01% 425
2025
Q3 		$11K Buy
28
+4
+17% +$1.67K ﹤0.01% 443
2025
Q2 		$10.7K Buy
24
+15
+167% +$6.91K ﹤0.01% 441
2025
Q1 		$4.36K Hold
9
– – ﹤0.01% 543
2024
Q4 		$3.62K Hold
9
– – ﹤0.01% 548
2024
Q3 		$4.19K Hold
9
– – ﹤0.01% 505
2024
Q2 		$4.22K Hold
9
– – ﹤0.01% 484
2024
Q1 		$3.76K Hold
9
– – ﹤0.01% 545
2023
Q4 		$3.66K Buy
+9
New +$3.33K ﹤0.01% 543

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Tidemark's VRTX Position: Q2 2026 in Review

Tidemark reduced its Vertex Pharmaceuticals (VRTX) stake by 3.8% in Q2 2026, selling an estimated $443 and leaving 25 shares worth $12.4K. The position accounts for ﹤0.01% of the portfolio, ranked #483.

Tidemark first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Tidemark held 25 shares of Vertex Pharmaceuticals worth $12.4K as of Q2 2026.
  • Tidemark sold 1 Vertex Pharmaceuticals share in Q2 2026, an estimated $443.
  • Vertex Pharmaceuticals made up ﹤0.01% of Tidemark's portfolio in Q2 2026, its #483 holding.
  • Tidemark first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Tidemark's 13F filing for Q2 2026, filed 10 Aug 2026.